{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:27:28Z","timestamp":1778567248305,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1124\/jpet.116.236497","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T13:25:36Z","timestamp":1478784336000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation"],"prefix":"10.1016","volume":"360","author":[{"given":"Yoshihiko","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Kuraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soma","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Onoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.236497_bib1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1517\/13543784.16.7.999","article-title":"Overactive bladder treatments in early phase clinical trials","volume":"16","author":"Colli","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.116.236497_bib2","first-page":"869","article-title":"Plasma pharmacokinetics and urinary excretion of propiverine hydrochloride in elderly population","volume":"34","author":"Cyong","year":"2006","journal-title":"Jpn Pharmacol Ther"},{"key":"10.1124\/jpet.116.236497_bib3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/TCRM.S6483","article-title":"Fesoterodine for the treatment of urinary incontinence and overactive bladder","volume":"5","author":"Ellsworth","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/jpet.116.236497_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1464-410X.2006.06258.x","article-title":"Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?","volume":"98","author":"Finney","year":"2006","journal-title":"BJU Int"},{"key":"10.1124\/jpet.116.236497_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1442-2042.2008.02152.x","article-title":"Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1124\/jpet.116.236497_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1442-2042.2009.02286.x","article-title":"A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"16","author":"Homma","year":"2009","journal-title":"Int J Urol"},{"key":"10.1124\/jpet.116.236497_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1442-2042.2008.02104.x","article-title":"A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1124\/jpet.116.236497_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11255-015-0916-1","article-title":"Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis","volume":"47","author":"Huang","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/jpet.116.236497_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1757-5672.2012.00147.x","article-title":"Effect of imidafenacin before sleeping on nocturia","volume":"4","author":"Kadekawa","year":"2012","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/jpet.116.236497_bib10","first-page":"92","article-title":"Effects of imidafenacin (KRP-197\/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland","volume":"57","author":"Kobayashi","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/jpet.116.236497_bib11","first-page":"147","article-title":"Pharmacological effects of imidafenacin (KRP-197\/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task","volume":"57","author":"Kobayashi","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/jpet.116.236497_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5414\/CPP43227","article-title":"Effect of age on the pharmacokinetics of solifenacin in men and women","volume":"43","author":"Krauwinkel","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/jpet.116.236497_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jphs.2016.06.002","article-title":"Characterization of muscarinic receptor binding by the novel radioligand, [(3)H]imidafenacin, in the bladder and other tissues of rats","volume":"131","author":"Kuraoka","year":"2016","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.116.236497_bib14","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.2174\/092986709789712835","article-title":"The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine","volume":"16","author":"Malhotra","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.116.236497_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00210-007-0207-1","article-title":"In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder","volume":"377","author":"Maruyama","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.116.236497_bib16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1124\/jpet.108.136390","article-title":"In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment","volume":"325","author":"Maruyama","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.236497_bib17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/bmc.837","article-title":"Development and validation of bioanalytical methods for imidafenacin (KRP-197\/ONO-8025) and its metabolites in human urine by using liquid chromatography-tandem mass spectrometry","volume":"21","author":"Masuda","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/jpet.116.236497_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2007.02999.x","article-title":"Absolute bioavailability of imidafenacin after oral administration to healthy subjects","volume":"65","author":"Ohno","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.116.236497_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/luts.12068","article-title":"Cognitive safety and overall tolerability of imidafenacin in clinical use: a long-term, open-label, post-marketing surveillance study","volume":"6","author":"Sakakibara","year":"2014","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/jpet.116.236497_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1757-5672.2011.00089.x","article-title":"Muscarinic receptor binding of imidafenacin in the human bladder mucosa and detrusor and parotid gland","volume":"3","author":"Seki","year":"2011","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/jpet.116.236497_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.110.172288","article-title":"Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder","volume":"336","author":"Yamada","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.236497_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroimage.2011.06.031","article-title":"Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [(11)C](+)3-MPB","volume":"58","author":"Yamamoto","year":"2011","journal-title":"Neuroimage"},{"key":"10.1124\/jpet.116.236497_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00210-011-0675-1","article-title":"In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats","volume":"384","author":"Yamazaki","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.116.236497_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1254\/jphs.09R14FM","article-title":"The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder","volume":"112","author":"Yoshida","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.116.236497_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.lfs.2010.06.008","article-title":"Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography","volume":"87","author":"Yoshida","year":"2010","journal-title":"Life Sci"},{"key":"10.1124\/jpet.116.236497_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1254\/jphs.13193FP","article-title":"Muscarinic receptor binding of the novel radioligand, [3h]imidafenacin in the human bladder and parotid gland","volume":"124","author":"Yoshida","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.116.236497_bib27","doi-asserted-by":"crossref","first-page":"854697","DOI":"10.1155\/2011\/854697","article-title":"Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, parallel-group trial (the LIST study)","volume":"2011","author":"Zaitsu","year":"2011","journal-title":"Adv Urol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652419475X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652419475X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.236497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:50:41Z","timestamp":1739994641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652419475X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S002235652419475X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.236497","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.236497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}